Effect of Pharmacogenetics on Imatinib Plasma Level and Response
Investigation of the Possible Role of Genetic Polymorphism in Certain Metabolizing Enzymes and Membrane Transporters on Both Plasma Level and Molecular Response of Imatinib in Patients With Chronic Myeloid Leukemia
Sponsor: Assiut University
This observational or N/A phase trial investigates Chronic Myeloid Leukemia and is currently completed. Assiut University leads this study, which shows 17 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Nov 2023 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Aug 2023 — Nov 2023 [monthly]
Active Not Recruiting
▶ Show 12 earlier versions
-
Sep 2022 — Aug 2023 [monthly]
Active Not Recruiting
-
Dec 2021 — Sep 2022 [monthly]
Active Not Recruiting
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Jul 2020 — Nov 2020 [monthly]
Active Not Recruiting
-
Sep 2019 — Jul 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jul 2018 — Sep 2019 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting
-
Apr 2018 — May 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assiut University
For direct contact, visit the study record on ClinicalTrials.gov .